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CLINICAL STUDY
Radiofrequency Ablation for the Palliative
Treatment of Bone Metastases: Outcomes
from the Multicenter OsteoCool Tumor
Ablation Post-Market Study (OPuS One
Study) in 100 Patients
Jason Levy, MD, Thomas Hopkins, MD, MBA, Jonathan Morris, MD,
Nam D. Tran, MD, PhD, Elizabeth David, MD, FRCPC,
Francesco Massari, MD, PhD, Hamed Farid, MD, MBA,
Alexander Vogel, MD, William G. O’Connell, MD, Peter Sunenshine, MD,
Robert Dixon, MD, Afshin Gangi, MD, PhD, Nicolas von der H€oh, MD, and
Sandeep Bagla, MD
ABSTRACT
Purpose: To evaluate the effectiveness of radiofrequency (RF) ablation as measured by change in worst pain score from baseline to 3
mo after RF ablation for the palliative treatment of painful bone metastases.
Materials and Methods: One hundred patients (mean age, 64.6 y) underwent RF ablation formetastatic bone disease andwere followed up
to 6 mo. Subjects’ pain and quality of life were measured before RF ablation and postoperatively by using the Brief Pain Index and European
Quality of Life questionnaires. Opioid agent use and device-, procedure-, and/or therapy-related adverse events (AEs) were collected.
Results: Eighty-seven patientswere treated for tumors involving the thoracolumbar spine and 13 for tumors located in the pelvis and/or sacrum.
All ablationswere technically successful, and97%were followedbycementoplasty.Meanworst pain score decreased from8.2±1.7 at baseline to
3.5± 3.2 at 6mo (n¼ 22;P< 0.0001 for all visits). Subjects experienced significant improvement for all visits in average pain (P< .0001), pain
interference (P< .0001), and quality of life (P < .003). Four AEs were reported, of which 2 resulted in hospitalization for pneumonia and res-
piratory failure. All 30 deaths reported during the study were attributed to the underlying malignancy and not related to the study procedure.
Conclusions: Results from this study show rapid (within 3 d) and statistically significant pain improvement with sustained long-term
relief through 6 mo in patients treated with RF ablation for metastatic bone disease.
ABBREVIATIONS
AE ¼ adverse event, BPI ¼ Brief Pain Inventory, PMMA ¼ polymethyl methacrylate, RF ¼ radiofrequency
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Current estimates report bone metastatic involvement in
60%–84% of cases in the presence of an underlying
neoplastic process, which can lead to morbidities (1). Pa-
tients in whom bone metastases develop may experience
pain, fracture, or neurologic injury. The annual health care
burden for the treatment of malignancy-related bone-related
complications is estimated at $12.6 billion (1). With the
growing incidence of cancer cases combined with the pro-
longed survival of patients as a result of effective chemo-
therapy and targeted therapies, the prevalence of patients
with bone metastases is increasing (2).
The primarygoals of the treatment of bonemetastases is pain
relief, reduction of delayed skeletal or neurologic events,
preservation of daily function, and optimization of quality of
life. Although first-line therapy usually consists of
bisphosphonates or targeted bone agents, external-beam radi-
ation therapy is considered the standard of care for symptom-
atic patients; however, pain relief often is not immediate and
may take as long as 4–6 weeks to be fully effective (3). Ste-
reotactic body radiation therapy has demonstrated higher rates
of palliation, ranging from 50% to 85%, but is associated with
fracture rates as high as 11%–39% (4–7). Surgical treatments
such as vertebrectomy, spinal reconstruction with cages,
pedicle screw internal fixation, Harrington-type acetabular
reconstruction, or other types of invasive therapies are available
to assist with pain relief and strengthen skeletal integrity;
however, these are associated with prolonged recovery time,
increased infection rates, and high morbidity and mortality
rates (8,9). In addition, these invasive procedures can delay
radiation therapy or other systemic therapies (10).
Minimally invasive ablation procedures with kyphoplasty
and polymethyl methacrylate (PMMA) augmentation have
been shown in randomized controlled studies to achieve
marked reduction in back pain and improvement in quality
of life with a decrease in opioid agent use (11). More
recently, several small observational studies of percutaneous
radiofrequency (RF) ablation have demonstrated pain relief
(8,12–16), mood and pain intensity improvements (13), and
decreased opioid agent use (12,16). The clinical goal of RF
ablation in vertebral metastases is primarily pain reduction
and tumor cavitation before stabilization (17,18). Recent
multidisciplinary treatment guidelines have outlined a
treatment paradigm whereby RF ablation may be considered
in conjunction with other therapies (19).
The purpose of this prospective, nonrandomized, multi-
center study was to evaluate the effectiveness of skeletal RF
ablation to demonstrate rapid (within 3 d) and sustained pain
improvement in patients with painful bone metastases. This
study provides the results in this cohort of patients.
MATERIALS AND METHODS
One hundred six patients were enrolled at 14 global investi-
gational centers betweenOctober 2017 andMarch 2019 in the
OsteoCool Tumor Ablation Post-Market (OPuS One) Study.
The study is projected to enroll a maximum of 250 patients as
long as 12 months after RF ablation. After enrollment, 6
subjects discontinued participation before undergoing RF
ablation (Fig 1). The present document reports the results in
the first 100 subjects treated with RF ablation. The present
institutional review board/ethics committee–approved pro-
spective study (clinicaltrials.gov identifier, NCT 03249584)
was conducted in compliance with federal Health Insurance
Portability and Accountability Act regulations. All patients
included were at least 18 years of age with metastatic tumors
of the thoracic and/or lumbar vertebral body/bodies, peri-
acetabulum, iliac crest, and/or sacrum andwere candidates for
RF ablation per the labeled indications. Exclusion criteria
included pure osteoblastic tumors, worst pain rated as< 4 on a
scale from 1 to 10 in the past 24 hours, more than 2 painful
sites requiring treatment, or Karnofsky performance score <
40 at enrollment. Included subjects had osteolytic bone me-
tastases confirmed by imaging or biopsy per physician
discretion. All procedures were considered technically suc-
cessful if RF ablation was delivered to the targeted tumor.
A total of 134 ablations were performed under imaging
guidance in the 100 patients. Sixty-eight patients (68%) had
a single target site treated with RF ablation, and 32 (32%)
had multiple sites treated. For those treated in the thoracic
and lumbar vertebrae, the majority (85%) of RF ablation
approaches were bilateral. Although not required per pro-
tocol, PMMA augmentation was performed in the majority
of cases (97%; 130 of 134). No patients underwent addi-
tional RF ablation procedures during the follow-up period.
Table 1 demonstrates patient characteristics and Table 2
reflects details of the ablation procedures.
Patient outcomes including pain, pain interference, and
quality of life were collected in a total of 94, 89, 64, 46, and
22 patients at 3 days, 1 week, 1 month, 3 months, and 6
months, respectively. A total of 40 patients discontinued
study participation after RF ablation treatment but before the
6-month follow-up, with 2 additional discontinuations after
6 months. The reasons for discontinuation included 30
deaths (71%), 9 voluntary patient withdrawals of consent
(21%), 2 losses to follow-up (5%), and 1 discontinuation
upon biopsy diagnosis of nonmalignant bone tumor (1%).
Chemotherapy (43%), steroids (39%), and osteoporosis
medications (38%) were reported as the most frequent
treatments after RF ablation.
RF Ablation Procedure
Ablation of the targeted tumor(s) was performed with the
OsteoCool RFAblation System (Sofamor Danek/Medtronic,
Dublin, Ireland). The system consists of an RF generator,
peristaltic pump, and the connector hub, which provides 2
channels for the use of the ablation probes and 2 channels
for the use of the optional independent thermocouples. The
bipolar ablation probe is a coaxial, bipolar technology that
provides localized tumor ablation and automatically adjusts
the power to maintain the RF heating within the desired
treatment range. The active tip of the RF ablation probe is
internally cooled with circulating sterile water in a closed-
loop system. RF energy heats the tissue while circulating
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water moderates the temperature in close proximity to the
active tip to minimize charring. The ablation volume and
time are determined based on the probe tip size.
All procedures were performed with computed tomogra-
phy (16%) or fluoroscopic guidance (84%) under moderate
sedation (30%), monitored anesthesia care (18%), or general
anesthesia (52%) per the institution’s standard of care. The
target tumors were accessed by using an 8- or 10-gauge
introducer cannula. In the thoracolumbar spine, the vertebral
bodies were accessed via a transpedicular or parapedicular
approach. The ablation probe lengths were predetermined and
placed through the access cannula. The RF ablation protocol
was performed by using the preset manufacturer algorithm. At
the completion of RF ablation, PMMA, if used, was injected
through the same bone access cannula.
Clinical Follow-up
Relevant cancer medical history and demographic informa-
tion was collected before the procedure. Patients completed
validated questionnaires to measure their pain, function, and
quality of life. The Brief Pain Inventory (BPI) short form is a
12-item self-administered questionnaire used to evaluate the
severity of a patient’s pain and the impact of this pain on the
patient’s daily functioning. For the purpose of this analysis, a
minimal clinically important difference in pain, as measured
by the BPI, was defined by a 2-point change from baseline
to postprocedural follow-up (20). The European Quality of
Life–Five Dimensions is a standardized measure of patients’
health status widely used as a validated tool to determine
health-related quality of life (21).
Follow-up assessments occurred after the ablation pro-
cedure, 3 days, 1 week, and 1, 3, and 6 months after the
procedure. Device-, therapy-, and/or procedure-related
adverse events (AEs) were collected through the follow-up
period.
Study Population
Patient demographic and baseline characteristics are pre-
sented in Table 1. A majority of the patients were female
(56%; 56 of 100), and the mean age was 64.6 years
(range, 30–89 y). The most common histology of the
underlying primary tumor was adenocarcinoma; lung
(25%) and breast (21%) were reported as the most
common primary cancer. Eighty-seven subjects (87%)
were treated for tumors involving the thoracolumbar spine,
and 13 subjects (13%) were treated for tumors located in the
pelvis and/or sacrum. Seventy-one percent of patients (71 of
100) reported concurrent treatments at baseline. Of these
treatments, steroids, chemotherapy, and osteoporosis medi-
cations were reported most often. At the baseline visit, 95
patients (95%) reported not currently receiving radiation at
the targeted tumor; only 5 patients (5%) reported undergo-
ing radiation in the target area previously.
Statistical Analysis
The primary objective was to achieve significant pain
improvement, from baseline to 3 months, in patients treated
with RF ablation for spinal metastases involving the thoracic
and/or lumbar vertebral body/bodies. A minimum sample
Figure 1. Study flow. The differences between counts at a visit and the next visit may not equate to the discontinued count because of
subjects who were still actively being followed at the time of manuscript preparation.
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size of 35 subjects completing the 3-month BPI worst pain
assessment was required to demonstrate an improvement of
 2 points. The results also include an expanded analysis
cohort by including subjects treated for metastatic tumors in
the periacetabulum, iliac crest, and/or sacrum.
Change from baseline was tested: a Shapiro–Wilk test P
value .05 prompted the use of aWilcoxon signed-rank test;
otherwise, a paired t test was used. For serial results over time,
if any visit showed a Shapiro–WilkP value .05, aWilcoxon
test was applied to all visits. The primary objective was
examined for significance at the 0.05 level; remaining addi-
tional measures were examined at 0.0025 following post-hoc
Bonferroni adjustment. Primary objective sensitivity analyses
included the use of multiple imputation and last observation
carried forward. SAS software (version 9.4; SAS, Cary, North
Carolina) was used for all analyses.
The trial was designed by the principal investigators (S.B,
J.L.) and the sponsor (Medtronic). The data were collected
by the individual sites and analyzed by the sponsor. The first
and last authors prepared the first draft, which was then
reviewed and edited by the other coauthors.
RESULTS
Outcomes
Following RF ablation, patients experienced significant
improvement in worst pain, average pain, pain interference,
Table 1. Patient and Tumor Characteristics
Characteristic Value












Colon, rectosigmoid 5 (5)
Liver 4 (4)












Lumbar and thoracic 10 (10)
Periacetabulum 4 (4)
Sacrum 3 (3)
Lumbar and iliac crest 2 (2)
Iliac crest 1 (1)
Sacrum and iliac crest 1 (1)
Lumbar and sacrum 1 (1)
Thoracic and sacrum 1 (1)





Type of treatment at baseline
Osteoporosis medications 33 (33)
Chemotherapy 33 (33)
Steroids 29 (29)
Radiation treatment at baseline
Yes 5 (5)
No 95 (95)
Note–Values in parentheses are percentages.
*Determined by biopsy after radiofrequency ablation.
†Before radiofrequency ablation.







Local conscious sedation 30 (30)




Ablation sites per subject
1 site 68 (68)
2 sites 30 (30)
3 sites* 2 (2)
Approach per ablation (134 ablations)
Vertebral ablation 120
Bilateral (2 probes) 102 (85)
Unilateral (1 probe) 18 (15)
Other locations 14
1 probe 3 (21)
2 probes 7 (50)
3 probes 2 (14)




Technical success 134 (100)
Note–Values in parentheses are percentages.
*Deviations documented for treating 3 sites.
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and quality of life. Before RF ablation, the mean score for
worst pain was 8.2 (Table 3). After ablation, worst pain
significantly improved, with mean scores decreasing to
5.6, 4.7, 3.9, 3.7, and 3.5 at 3 days, 1 week, 1 month, 3
months, and 6 months, respectively (P < .0001 for all
visits; Fig 2). More than half of patients (59%)
experienced immediate improvement, reporting a  2-
point change in worst pain at the targeted treatment site(s)
3 days after ablation. Worst pain continued to improve, with
approximately 75%, 83%, and 86% of patients reporting 
2-point improvement at the 1-, 3-, and 6-month visits,
respectively. The vertebral-treated subject subgroup
included in the primary objective experienced a mean
improvement in worst pain from 7.8 at baseline to 3.6 at 3
months (P < .0001; Table 4). To assess any impact of
dropout on this result, 2 preplanned sensitivity analyses
were performed. These confirmed that the change in pain
from baseline to 3 months is robust to missing data, as the
analyses demonstrated results consistent with those of
only subjects with complete data.
Decreases in average pain were also observed. Before RF
ablation, patients reported an average pain score of 6.0
(mean). Average pain score improved, with means reported
as 4.0, 3.3, 2.8, 2.8, and 2.9 at 3 days, 1 week, 1 month, 3
months, and 6 months, respectively (P < .0001 for all
visits). Three days after ablation, 51% of patients were
considered to have a clinically relevant change in average
pain. This increased to 67% after 1 month and further
increased to 77% at the 6-month visit.
Quality of life and pain interference with patient’s func-
tionality was also assessed before and after the procedure.
The mean European Quality of Life index was 0.48 at
baseline. Following RF ablation, it improved to 0.58, 0.64,
0.69, 0.66, and 0.69 at 3 days, 1 week, 1 month, 3 months,
and 6 months, respectively, corresponding to respective
mean changes (improvements) from baseline
of þ0.09, þ0.15, þ0.17, þ0.15, and þ0.21 (P  .003 for all
visits). The degree of pain interference with patient func-
tionality per BPI showed improvement, with the mean de-
gree of interference decreasing consistently over time after
ablation from baseline (6.1) to 4.1, 3.1, 2.9, 2.8, and 2.5 at
the respective scheduled follow-up visits (P < .0001 for all
visits). Eighty-four subjects (84%) did not report receiving
any radiation treatments at the targeted area after RF abla-
tion. Data were collected on transdermal and/or oral narcotic
agents taken 24 hours before each visit. Data were then
converted into morphine equivalent dose. Mean oral
morphine equivalent 24-hour dose for all treated subjects at
baseline was 61.0 mg, and it decreased to 50.4 mg at the 3-
month visit.
Four AEs were reported, of which 2 resulted in hospi-
talization for pneumonia and respiratory failure, respec-
tively. Thirty deaths were reported during the course of the
study, with 29 through the 6-month visit. All deaths were














Mean score ± SD 8.2 ± 1.7 5.6 ± 2.7 4.7 ± 2.9 3.9 ± 3.0 3.7 ± 2.9 3.5 ± 3.2
Median 8.0 5.0 5.0 4.0 3.0 3.0
P value (Wilcoxon) – < .0001 < .0001 < .0001 < .0001 < .0001
95% CI of change – –3.1 to –1.9 –3.9 to –2.7 –4.7 to –3.1 –5.1 to –3.1 –6.2 to –3.5
Subjects with  2-point change (%) – 59 66 75 83 86
BPI average pain
Mean score ± SD 6.0 ± 2.1 4.0 ± 2.3 3.3 ± 2.3 2.8 ± 2.2 2.8 ± 2.4 2.9 ± 2.5
Median 6.0 4.0 4.0 3.0 3.0 3.0
P value (Wilcoxon) – < .0001 < .0001 < .0001 < .0001 < .0001
95% CI of change – –2.5 to –1.4 –3.3 to –2.1 –3.4 to –2.1 –3.6 to –2.1 –4.4 to –2.1
Subjects with  2-point change (%) – 51 62 67 74 77
BPI pain interference score
Mean score ± SD 6.1 ± 2.3 4.1 ± 2.8 3.1 ± 2.7 2.9 ± 2.5 2.8 ± 2.7 2.5 ± 2.5
Median 6.0 3.9 2.4 2.6 2.1 1.3
P value (t test) – < .0001 < .0001 < .0001 < .0001 < .0001
95% CI of change – –2.4 to –1.4 –3.5 to –2.3 –3.5 to –2.2 –3.9 to –2.1 –4.7 to –2.6
EQ-5D index
Mean score ± SD 0.48 ± 0.32 0.58 ± 0.33 0.64 ± 0.28 0.69 ± 0.21 0.66 ± 0.26 0.69 ± 0.24
Median 0.59 0.69 0.70 0.71 0.70 0.69
P value (Wilcoxon) – .0018 < .0001 < .0001 .0021 .0006
95% CI of change – 0.03–0.15 0.10–0.21 0.10–0.24 0.05–0.25 0.09–0.34
Note–95% CIs are the 95% 2-sided CIs for the change from baseline.
BPI ¼ Brief Pain Inventory; CI ¼ confidence interval EQ-5D ¼ European Quality of Life–Five Dimensions.
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classified by the clinical events committee and investigator
to be attributed to underlying malignancy and not related to
RF ablation.
DISCUSSION
The primary analysis of the prospective OPuS One Study
shows rapid and significant pain improvement at 3 days
after RF ablation and sustained significant long-term relief
through 6 months in patients with metastatic bone disease
treated in real-world settings. The results also show signif-
icantly improved quality of life and significantly increased
function in patients with painful bone metastasis. The rapid
and sustained pain-relief results after treatment with the RF
ablation system were clinically impactful given the
advanced disease state of this cohort of patients.
Three days after the ablation procedure, more than half of
patients experienced clinically relevant improvement with a
minimum 2-point decrease in worst pain score. Patients
continued to have substantial pain improvement, with
approximately 75% experiencing clinically relevant
improvement at 1 month and more than 85% at 6 months.
Average pain also showed consistent significant improve-
ment over time. Quality of life and the degree of pain
interference with daily activities improved significantly
compared with before ablation.
External-beam radiation therapy is the current standard of
care for the treatment of bone metastases. Although radia-
tion therapy is noninvasive, it has several important limi-
tations (22). Pain relief with external-beam radiation therapy
can take as long as 4–6 weeks after treatment completion,
and pain response rates are estimated at 60% (3,23).
Although the use of stereotactic body radiation therapy has
increased, especially in oligometastatic disease, radiation-
induced vertebral compression fractures are reported in
11%–39% of cases (24). Because of tissue tolerance, there is
also a potential inability to repeat radiation therapy at the
same site if the pain persists (12). The present study is
unique, as the majority of patients reported no previous
radiation at the treated site at baseline. Given the radiation-
Figure 2. BPI scores for worst pain, average pain, and pain interference. Change from baseline is significant at all time points (P <.0001)
for all 3 measures.
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naivety of this cohort of patients at baseline, the results
indicate that the effects of pain relief can be attributed to the
study procedure. Forty-six percent of patients had metastatic
lung or breast cancer, which is typically radiation-sensitive,
but patients in this study experienced clinically impactful
pain relief quickly, within 3 days after RF ablation. Other
RF ablation studies were limited in their evaluation of pain
response by the confounding variable of previous radiation
treatment (16,25). In addition, in the present study, only
16% of patients received radiation at the ablation site after
RF ablation.
No postprocedural fractures at the ablation site(s) were
reported in this study, suggesting that RF ablation with
PMMA augmentation can address biologic pain while pro-
tecting against future mechanical failures. This study did not
have any symptomatic PMMA leakage complications that
have been previously reported in other studies (26). Four
AEs were reported, with 2 resulting in hospitalization for
pneumonia and respiratory failure, respectively. All 30
deaths reported during the study were classified by the in-
dependent clinical events committee and investigators as not
related to the RF ablation procedure, therapy, or device and
attributed to the natural progression of the disease.
The limitations of the present study include the difficulty
to discern the impact of RF ablation alone as a result of the
use of PMMA augmentation. The study of Berenson et al
(11) previously demonstrated that kyphoplasty alone can
improve pain control in patients with cancer with painful
compression fractures at 1 month and maybe as early as 1
week. The potential combined benefit of tumor ablation for
biologic pain and prevention of delayed skeletal events with
the administration of PMMA for mechanical stabilization
and mechanical pain was likely complementary. This be-
comes more important in the patient population of the pre-
sent study, given that the inclusion criteria included
predominantly axial weight-loading bones, thoracolumbar
spine, and periacetabular locations, where mechanical sta-
bilization is crucial. For those reasons, it is unlikely that
these 2 therapies will ever be studied separately in the same
prospective trial. Additionally, the use of only oral and
transdermal narcotic agents was collected; intravenous
administration of narcotic agents was not collected, which
could confound the study results. In the authors’ opinion,
given that intravenous narcotic agents are more likely to be
given in an inpatient setting and follow-up was predomi-
nantly on an outpatient basis, this might suggest that the
pain reduction could have actually been underestimated.
Finally, the high mortality rate in this cohort (30%, with 16
of 30 dying before the 1-mo visit) implies that RF ablation
was provided as palliative treatment at the end of the care
continuum, with more severe symptoms, rather than earlier
in therapy, when recurrence or disease progression may be
more likely. The high mortality rate in the present cohort
(30%) is comparable to the high mortality rate previously
reported (> 20% at 6 mo) for patients undergoing surgical
treatment for cancer-associated compression fractures (11).
In conclusion, considering the rapid and long-lasting
significant pain relief and high degree of safety shown in
the present study, RF ablation of axial skeletal metastases is
a viable treatment option. As suggested by more recent
multidisciplinary guidelines, RF ablation with cemento-
plasty has become one of the ideal treatment modalities that
may be performed alone or in combination with radiation
therapy in the treatment of metastatic bone disease.
Consideration of this therapy sooner in the care continuum
to maximize its palliative benefits in metastatic bone disease
is a potential future direction. Other future studies could be
targeted to imaging-based local tumor control assessment,
comparison of tumor reduction with and without adjunctive
external-beam radiation therapy, and potential for reduction
in fractures versus radiation therapy alone.
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